-+ 0.00%
-+ 0.00%
-+ 0.00%

The Safety Monitoring Committee Concluded Its Planned Safety Review For All Patients Treated With The INTASYL compound PH-762 In Phio Pharmaceuticals' Phase 1b Trial, No Serious Adverse Events Or Dose-limiting Toxicities Identified

Benzinga·02/10/2026 12:09:49
Listen to the news

Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 Responders